Methods and compositions for treatment of HSV-2 infections and c

Details Methods and compositions for treatment of HSV-2 infections and c Methods and compositions for treatment of HSV-2 infections and c

1996-09-06

1999-07-13

Smith, Lynette F.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4242051, 4242041, 4241991, 424 932, 424 936, 435236, A61K 39245, A61K 3912, A01N 6300

Patent

active

059223286

ABSTRACT:
A live, attenuated HSV-2 virus and methods of making and using the virus are provided. The live, attenuated HSV-2 virus is constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions. Additionally, a plasmid vector is disclosed for expressing a GST-UL56 fusion protein wherein the protein comprises the Glutathione S Transferase gene product fused to at least an immunogenic portion of the HSV-2 UL56 gene product. The GST-UL56 fusion protein can be used to produce polyclonal antisera to the HSV-2 UL56 gene product, to detect whether recombinant HSV-2 deletion mutants express UL56, and as a type-specific reagent capable of discerning HSV-1 from HSV-2.

REFERENCES:
patent: 5328688 (1994-07-01), Roizman
Bolovan et al. J. Virol. 68(1): 48-55, 1994.
Laure Aurelian "Herpes Simplex Viruses" In: Encyclopedia of Virology, vol. II, Webster and Granoff, eds., Academic Press Limited, London, pp. 5878-5593, 1994.
Whitley, Replication, Establishment of Latency, and Induced Reactivation of Herpes Simplex Virus .gamma.1 34.5 Deletion Mutants in Rodent Models, J Clin Invest 91: 2837-43 (1993).
Kehm, In Vitro Expression of UL56 Gene of Herpes simplex Virus Type 1, Virus Res 33: 55-66(1994).
Meignier, In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020, J Inf Dis 162: 313-21(1990).
Nash & Spivack, The UL55 and UL56 Genes of Herpes Simplex Virus Type 1 Are Not Required for Viral Replication, Intraperitoneal Virulence, or Establishment of Latency in Mice, Virology 204: 794-98(1994).
Inglis, Challenges and Progress in Developing Herpesvirus Vaccines, Tibtech vol. 13, pp. 135-142 (Apr. 1995).
Chou, Mapping of Herpes Simplex Virus 1 Neurovirulence to .gamma.1 34.5, a Gene Nonessential for Growth in Culture, Science 250: 1262-66(1990).
McGeoch, Comparative Sequence Analysis of the Long Repeat Regions and Adjoining Parts of the Long Unique Regions in the Genomes of Herpes Simplex Viruses Types 1 and 2, J Gen Virol 72: 3057-75(1991).

Affiliated with

Also associated with

Rating

Methods and compositions for treatment of HSV-2 infections and c does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treatment of HSV-2 infections and c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of HSV-2 infections and c will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2273500